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Abstract
Background: Prostate cancer involving the rectal wall is rare and may lead to diagnostic pitfalls.
Case presentation: Out of 9504 patients with rectal tumors between January 2003 and January 2015, 9 patients
(elderly with a mean age of 74 years) with prostate cancer involving the rectal wall were clinically misdiagnosed
with rectal cancer. The lesions were located in the rectum, and included 3 circumferential rectal masses, 1
ulceration lesion, 1 crater-like mass, and 4 protruding lesions. Specimens were acquired using biopsy, fine needle
aspiration, or resection. The initial symptoms of these patients included rectal urgency, bowel obstruction, and
lower gastrointestinal bleeding. Prostate-related symptoms were not obvious. Histologically, 2 cases showed cancer
cell invasion in the mucosa, 1 showed transmural invasion from the mucosa to subserosal soft tissues, and 7 cases
had submucosa and muscularis propria involvement. All the 9 cases had muscularis propria involvement. However,
there were no intraepithelial neoplasias in the mucosal layer, which is reminiscent of rectal carcinoma. The tumors
consisted of small-sized or foamy cells that formed acinus-like, duct-like, and cribriform-like structures. We
conducted histological staining and an immunohistochemical analysis for CDX-2, prostate-specific antigen (PSA),
P504s, villin, carcinoembryonic antigen, CK-pan, cytokeratin 20, and Ki-67. All tumors were PSA and CK-pan positive,
5 of 9 tumors were P504s-positive, and all tumors were negative for the other markers. All patients underwent
standard therapy for prostate cancer after the definitive pathological diagnosis. As of March 31, 2015, 8 patients
were alive and 1 had died of prostate cancer 6 months posttreatment.
Conclusions: Adenocarcinoma appearing in the rectal wall is not always rectal carcinoma. It is necessary to
perform a differential diagnosis for prostate cancer in cases of rectal malignant tumors in elderly male patients. Any
treatment should be postponed until the final definitive diagnosis is reached.
Background
Prostate cancer is the second most frequently diagnosed
cancer and the fifth leading cause of cancer death among
men worldwide [1]. In China, the incidence rate of
prostate cancer was 1.6/100 000 individuals. However,
its incidence has been increasing each year [2]. Prostate
cancer risk factors include a family history of the disease,
ethnicity, and in particular older age [3], with most cases
occurring in men older than 50 years [4–6]. With more
comprehensive screening techniques being increasingly
used in China, the incidence of prostate cancer may
rapidly increase in the future [2].
The prostate is located in the pelvis, under the urinary
bladder and in front of the rectum. Because of its
location, prostate cancer often affects urination, ejacula-
tion, and more rarely, defecation. Prostate cancer may
invade the nearby organs including the rectum, bladder,
and ureters, and metastasize to the bones and lymph
nodes [7–9]. The presenting symptoms include difficulty
urinating, blood in the urine, and pelvic pain [10, 11].
Because of its proximity to the rectum, prostate cancer
can be misdiagnosed as rectal cancer.
There is a thick capsule (Denonvilliers’ fascia) between
the prostate and rectal wall [12], and prostate cancer
accompanied by rectal invasion is rare [13, 14]. In the
present study, we retrospectively analyzed 9504 cases
diagnosed as rectal cancer in our hospital from 2003 to
2015, and report the clinicopathological characteristics
of 9 cases of prostate cancer with rectal wall invasion
misdiagnosed as rectal cancer. In these 9 patients, the
initial symptoms in 8 patients were rectal urgency, bowel
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obstruction, and lower gastrointestinal bleeding, and
prostate-related symptoms were not obvious. A defini-
tive diagnosis of prostate cancer invading the rectum
can be made based on the patients’ history, the
morphological features of the cancer, and immuno-
histochemical (IHC) analyses. Furthermore, the serum
prostate-specific antigen (PSA) levels and the ratio of




This study was approved by the Institutional Review
Board of Tianjin Union Medicine Center, and the pa-
tients’ anonymity has been maintained. The surgical
pathology database at the Department of Pathology
(2003–2015) was searched for cases of prostate cancer
with rectal wall involvement. Nine elderly patients with
such cancer, with a mean age of 74.75 ± 7.19 years, were
included. Specimens were obtained using biopsy in 5
patients, fine needle aspiration (FNA) in 3 patients, and
surgical resection in 1 patient who underwent 3 months
of chemotherapy prior to surgery to shrink the tumor.
Clinical characteristics and findings
The clinical characteristics and macroscopic findings are
summarized in Table 1. The mean patient age was
74 years (range, 64–85 years). Eight patients (64.3%) had
no prior history of prostate cancer, whereas 1 had a
history of prostate cancer (9 years earlier). Symptoms
included a change in bowel movements (n = 4), rectal
urgency (n = 4), pelvic pain (n = 1), rectal mass (n = 2),
and lower gastrointestinal bleeding (n = 2). Only 1 pa-
tient had prostate-related symptoms including urinary
frequency, difficulty in urination, and painful urination.
Endoscopy revealed that the tumor masses were
located at 2–7 cm away from the anus, and ranged 1–
6 cm in size. Grossly, the tumors included circumferen-
tial rectal masses (n = 3), an ulceration lesion (n = 1), a
crater-like mass (n = 1), and protruding lesions (n = 4).
In 7 patients, serum PSA levels were 6–10 times higher
than the upper limit of the normal level; the PSA level
was not recorded in 2 patients. The ratio of free PSA to
unbound PSA was low in all 9 patients. The primary
clinical impression in these cases was rectal carcinoma
(n = 7), gastrointestinal stromal tumor (n = 1), and
prostate cancer involving the rectum (n = 1).
Histopathological examination
A summary of the histopathological findings is presented
in Table 2. There was no evidence of intraepithelial
neoplasia in any case. There were 2 cases of cancer cell
invasion in the mucosa, 7 cases of submucosa invasion,
and all cases had muscularis propria involvement. The
Gleason score system is based on the degree of glandular
architecture, differentiation, and the tumor growth
pattern, and is by far the best predictor of prostate
tumor progression and prognosis. The Gleason score in
all patients was ≥7 (Table 2).
Microscopically, the tumors exhibited a wide spectrum
of appearances including foamy glands caused by accu-
mulation of lipids (Fig. 1A -a), small glands (Fig. 1A -b),
diffuse individual cell infiltration (Fig. 1A -c and A -d),
and cribriform structures (Fig. 1A -e). In the foamy
gland carcinomas, the tumor cells were large, cuboidal,
or columnar-shaped, with small and round nuclei and
conspicuous nucleoli. The behavior of the foamy gland
carcinomas was aggressive with metastases to the lymph
tissue (Fig. 1A -g). Furthermore, these architectural pat-
terns were accompanied by cytological abnormalities in
the form of nuclear enlargement, inconsistent nucleus
size, and prominent nucleoli.
In the 9 patients with prostate cancer, 3 had small-
sized glands and 2 had medium-sized glands. Diffuse
individual cell infiltration was seen in 4 tumors. Lymph
vessel emboli were apparent in 2 patients (Fig. 1A -f ),
and lymph tissue metastatic foci could be observed in 3
patients (Fig. 1A -g). Glomeruloid structure (Fig.1A -h),
a morphologic feature used in the diagnosis of prostate
cancer, could be found in the rectal foci derived from
the prostate cancers. The presence of prostatic cancer
cells within the perineural spaces was seen in 4 patients
(Fig.1A -i), a morphological feature for pathologic diag-
nosis of a malignant tumor.
Immunohistochemical findings
All tumors were PSA and CK-pan positive. Six tumors
were P504s-positive. Staining for CK20, villin, and
CDX2, which are important indicators of tumors derived
from the digestive system, were negative (Fig. 2A -C).
Fig. 2 shows the IHC findings in 3 cases of prostate can-
cer involving the rectum. In these 3 cases, the results of
hematoxylin and eosin staining showed atypical cells and
glandular architectures distributed among the rectal epi-
thelial cells (Fig. 2A -a, B -a and C -a). These atypical
cells were positive for CK-pan IHC staining (Fig. 2A -b,
B -b and C -b), which confirms their origin as epithelial.
The cancer cells in all 3 cases were strongly positive for
PSA (Fig. 2A -c, B –c, and C -c) and P504s (Fig. 2A -d,
B -d and C -d). In all 3 cases, the cancer cells were nega-
tive for CDX-2, villin, and CK20 (Fig. 2A -e, B -e, C -e).
Follow-up information was available for all patients.
As of March 31, 2015, 8 patients were alive at follow-up
(mean, 47.75 months; range, 8–87 months). The 7
patients who underwent surgical resection and endo-
crine therapy based on a diagnosis of prostate cancer
were still alive. The patient with a prostate cancer
history underwent endocrine therapy and surgical
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resection and is still alive. One patient who under-
went surgical resection and subsequently underwent
standard rectal cancer therapy died 6 months post-
treatment because of extensive metastases from the
prostate cancer.
Discussion
Prostate cancer most commonly metastasizes to the
bones and lymph nodes or directly infiltrates to the
bladder and ureters [16]. Digestive tract metastasis from
prostate adenocarcinoma is relatively rare. There is a
thick layer of fascia (Denonvilliers’ fascia) between the
prostate and the rectum, making it difficult for prostate
cancer to invade the rectum. There are 3 potential
routes for prostate cancer to invade the rectal wall,
including prostate cancer directly invading through
Denonvilliers’ fascia and infiltration into the rectum,
lymphatic metastasis, and prostate cancer cells spreading
through needle biopsy to seed into peri-rectal or
rectal tissue [7].
Because the morphologic features of prostate cancer
and rectal adenocarcinoma are similar, there is a risk of
misdiagnosis, which can have adverse consequences for
the patient because of the subsequent use of inappropriate
treatment strategies [7, 17]. There are fundamental differ-
ences in treatment for these two kinds of malignancy.
Treatment of aggressive prostate cancers may involve
surgery, radiation therapy, chemotherapy, or combination
therapy [18–20]. In addition, some elderly patients are not
offered curative treatment options and instead made to
undergo hormonal therapy or careful observation [21].
Furthermore, hormonal therapy and chemotherapy are
often reserved for disease that has spread beyond the
prostate. In contrast, for localized rectal cancer, the
preferred treatment is complete surgical resection with
adequate margins, although chemotherapy is often used
preoperatively to shrink the tumor.
Here, we reviewed the data of 9 patients with prostate
cancer involving the rectal wall, only 1 of whom had a
history of prostate cancer. They were all clinically diag-
nosed with rectal carcinoma. One patient who under-
went chemotherapy for a clinical diagnosis of rectal
carcinoma, prior to the correct diagnosis of prostate
cancer, died shortly after treatment because of prostate
cancer metastasis, which emphasizes the importance of
an accurate and timely diagnosis.
Fig. 1 A. Morphological characteristics of prostate cancer involving the rectal wall. a. Foamy glands (black arrow heads). b. Small glands (black
arrow heads). c. Diffuse individual cell infiltration (black arrow heads). d. Small prostate cancer cells infiltrating the muscularis propria (black arrow
heads). e Cribriform structure (black arrow heads). f. Emboli in the lymph-vessels of the mucosal layer (black arrow heads). g. Lymph tissue metasta-
sis (black arrow heads). h. Glomeruloid structures (black arrow heads). i. Perineural capsular invasion (black arrow heads). All images are hematoxylin
and eosin (H&E) sections with a magnification of × 200
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Rectal examination is an efficient method for the
detection of prostate cancer. However, a pathological
confirmation using biopsy or FNA is necessary for a
definitive diagnosis of prostate cancer [22, 23] because
of the high incidence of both cancers in elderly patients.
Differences in pathology between prostate and rectal
cancers, including cytoarchitecture, glandular architec-
ture, cellular pleomorphism, and mucosecretion pat-
terns, can facilitate a correct diagnosis [24]. In rectal
adenocarcinoma, tumor cells form irregular tubular
structures, have multiple lumens, and have reduced
stroma [25]. In contrast, prostate cancer glands have
irregular outlines with a smooth inner surface. In
addition, the epithelial cells in the rectal mucosa often
exhibit intraepithelial neoplasia [26]. In the present
study, there was no evidence of intraepithelial neoplasia
in the rectal mucosa layer, suggesting that the tumors
may be not rectal carcinomas. Furthermore, the tumor
cells in the present study exhibited the 4 major cyto-
architectural patterns associated with prostate cancer
including medium-sized glands, small glands, diffuse
individual cell infiltration, and cribriform patterns. The
prostate cancer cells present with nuclear enlargement
and prominent nucleoli [26, 27].
IHC to identify specific markers of prostate and colo-
rectal cancers plays an important role in confirming the
origin of the tumor. Liu et al. reported that IHC staining
is an essential tool in distinguishing the origin of meta-
static cancer, particularly in cases where the histology
does not appear typical of rectal carcinoma [15]. PSA
and P504s are both specific, accurate, commonly used
markers of prostate cancer cells. PSA is secreted specif-
ically by the epithelial cells of the prostate gland [28],
and PSA serum levels are often elevated in patients with
prostate cancer [29, 30]. In the blood, the majority of
PSA is bound to serum proteins with a small fraction of
unbound PSA. Therefore, in patients with prostate can-
cer, the ratio of free PSA to unbound PSA is significantly
decreased, providing a powerful diagnostic tool [31].
P504s is a highly sensitive marker for prostate cancer
that is useful for the detection of small foci in biopsy
and FNA specimens [32, 33]. However, P504s is not
always present in prostate cancer because the degree of
tumor differentiation can affect its expression. Further-
more, in contrast to rectal cancer, prostate cancer is
rarely positive for CK20 [34–36]. Villin is localized to
the microvilli of the brush border of the intestinal epi-
thelium and is a good marker of adenocarcinomas of
Fig. 2 H&E and immunohistochemical (IHC) staining in 3 cases of prostate cancer involving the rectal wall. A. IHC staining confirmed the
diagnosis of prostate cancer in case 1 (all images, except a, are of IHC staining, magnified × 200). a. H&E staining of case 1 (Gleason score 5 + 4).
b. Strong positive expression of CK in prostate cancer and mucosal epithelial cells. c and d. The cancer cells are strongly positive for PSA and
P504s, whereas the epithelial cells of the rectal mucosa are negative. e. The cancer cells are negative for CDX2. B. IHC staining confirmed the
diagnosis of prostate cancer in case 2 (all images, except a, are of IHC staining, magnified × 200, except b, magnified × 100). a. H&E staining of
case 1 (Gleason score 4 + 3). b. Positive expression of CK in cancer cells. c. Strong positive expression of PSA in cancer cells with no expression in
rectal epithelial cells. d. Strongly positive expression of P504s in cancer cells. e. The cancer cells are negative for villin. C. IHC staining confirmed
the diagnosis of prostate cancer in case 3 (all images, except a, are of IHC staining, magnified × 200). a. H&E staining in case 3 (Gleason score 4 +
4). b. The cancer cells are weakly positive for CK and the epithelial cells are strongly positive. c and d. The cancer cells are strongly positive for
PSA and P504s. e. The cancer cells are negative for CK20
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intestinal origin. CDX2 is a highly sensitive and specific
marker of adenocarcinomas of intestinal origin [37].
In the present study, all tumors were positive for PSA,
and 6 tumors were positive for P504s. In contrast, all
tumors were negative for CK20, CDX2, and villin
[38–40]. In addition, all these tumors were negative
for CDX-2; however, some androgen-independent prostate
tumors display nuclear CDX2 staining [41], which could
represent a potential dangerous pitfall for the differential
diagnosis from rectal carcinoma.
Conclusions
In the present study, we identified a number of consider-
ations to keep in mind when making a differential diag-
nosis of prostate cancer. First, most colorectal cancers
arise from adenomatous polyps [42, 43] and transitional
lesions (low-grade or high-grade intraepithelial neopla-
sia) between the normal epithelium and carcinoma, and
often appear in the rectal mucosal layer, which can help
judge the origination of rectal lesions. Intraepithelial
neoplasia does not occur in rectal metastatic tumors
derived from prostate cancer. Second, the medical his-
tory of the patient should be carefully evaluated because
1 of the patients in this study presented with a history of
prostate cancer. When a tumor mass appears in the rec-
tal wall of patients with a medical history of prostate
cancer, the diagnosis of rectal cancer should only be
reached after prostate cancer has been ruled out. Third,
IHC staining for tissue-specific markers provides signifi-
cant support, enabling pathologists to determine an ac-
curate and definitive diagnosis. Furthermore, in elderly
male patients who have a tumor mass in the rectum, the
differential diagnosis of prostate cancer must be per-
formed to avoid misdiagnosis. Any treatment should be
postponed until the final definitive diagnosis is reached.
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